RESUMEN
OBJECTIVE: Genetic studies have suggested that the serotonin transporter (SERT) could be associated with cigarette smoking. However, evidence from neuroimaging is scarce. The aim of the present study was to examine the SERT availability among cigarette smokers by using single-photon emission computed tomography (SPECT). METHODS: Sixteen male smokers and 32 controls were enrolled. The SERT availability was measured by SPECT with a radiotracer, [I] ADAM, which is highly sensitive and specific to SERT. RESULTS: No significant difference in SERT availability was found between 2 groups in the midbrain (smokers: 2.12â±â0.70, nonsmokers: 2.13â±â0.63; Pâ=â0.86), basal ganglia (smokers: 0.83â±â0.30, nonsmokers:0.90â±â0.39; Pâ=â0.95), or thalamus (smokers: 1.14â±â0.41, nonsmokers: 1.20â±â0.38; Pâ=â0.88). No significant association was found between the SERT availability, and either the breath carbon monoxide level or the score of the Fagerström Test for Nicotine Dependence. CONCLUSIONS: Whether the SERT availability in the brain is altered in smokers remains unclear.
Asunto(s)
Cinanserina/análogos & derivados , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Fumar/metabolismo , Tomografía Computarizada de Emisión de Fotón Único , Adulto , Ganglios Basales/metabolismo , Estudios de Casos y Controles , Cinanserina/metabolismo , Neuroimagen Funcional , Humanos , Radioisótopos de Yodo/metabolismo , Masculino , Mesencéfalo/metabolismo , Persona de Mediana Edad , Tálamo/metabolismo , Adulto JovenRESUMEN
INTRODUCTION: Serotonin may play an important role in the pathology of major depressive disorder (MDD). However, the relationship between serotonin transporter (SERT) availability and the medical outcome of antidepressant treatment is uncertain. METHODS: In this naturalistic study, SERT availability (expressed as the specific uptake ratio, SUR) in the midbrain of 17 drug-free patients with MDD and 17 controls matched for age and gender was measured using SPECT with [(123)I]ADAM. The severity of MDD was measured by the Hamilton Depression Rating Scale before, and after 6 weeks of non-standardized antidepressant treatment. RESULTS: A total of 12 patients completed the study. The SUR of the patients with MDD was significantly lower than that of the healthy controls. The SUR of SERT was not found to have a linear relationship with the treatment outcome; however, supplemental analysis found a curvilinear relationship between treatment outcome and the SUR of SERT. DISCUSSION: The findings indicate that the SUR of SERT is lower in patients with MDD; however it did not predict treatment outcome in a linear fashion. Studies with larger sample sizes are required.
Asunto(s)
Antidepresivos/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Trastorno Depresivo Mayor/metabolismo , Mesencéfalo/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Adulto , Estudios de Casos y Controles , Cinanserina/análogos & derivados , Cinanserina/metabolismo , Femenino , Neuroimagen Funcional , Humanos , Radioisótopos de Yodo , Masculino , Persona de Mediana Edad , Radiofármacos , Tomografía Computarizada de Emisión de Fotón Único , Resultado del Tratamiento , Adulto JovenRESUMEN
RATIONALE AND OBJECTIVE: Although loudness dependence of auditory evoked potentials (LDAEPs) had been suggested as a noninvasive measure of central serotonin functions, recent studies suggest that LDAEP may be modulated by multiple neuromodulatory systems, such as dopamine. Here, we explore the relationship between LDAEP and dopamine and serotonin in the level of monoamine transporter availability. METHODS: Forty-nine healthy volunteers received LDAEP and single-photon emission computed tomography (SPECT) using [(99m)Tc] TRODAT and [(123)I] ADAM to approximate the availability of dopamine transporters (DATs) and serotonin transporters (SERTs). RESULTS: LDAEP was found to be positively associated with DAT, after adjusting for age and gender, and the log-transformed slope of loudness dependence at Cz was negatively associated with SERT. CONCLUSION: Our findings provide further evidence for the possible involvement of dopamine and serotonins in the genesis of LDAEP.
Asunto(s)
Encéfalo/diagnóstico por imagen , Encéfalo/fisiología , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Potenciales Evocados Auditivos/fisiología , Percepción Sonora/fisiología , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Estimulación Acústica/métodos , Adulto , Mapeo Encefálico , Cinanserina/análogos & derivados , Femenino , Humanos , Masculino , Persona de Mediana Edad , Compuestos de Organotecnecio , Radiofármacos , Análisis de Regresión , Tomografía Computarizada de Emisión de Fotón Único/métodos , Tropanos , Adulto JovenRESUMEN
The in vivo assessment of brain serotonergic function might be of clinical relevance in neuropsychiatry. The loudness dependence of auditory evoked potentials (LD) has been proposed as an indirect indicator of cortical serotonergic activity, whereas single photon emission computed tomography (SPECT) and [123I]ADAM allow the selective assessment of brain serotonin transporters (SERT). The aim of this study was to investigate LD and SERT availability as independent variables of the brain serotonergic system in healthy volunteers. Fifteen (six male, nine female) subjects received both neurophysiological and imaging investigations. Evoked potentials were recorded following the application of acoustic stimuli with increasing intensities; the LD was analyzed using dipole source analysis. SPECT was performed four hours after injection of 137 +/- 11.4 MBq [123I]ADAM. As a measure of SERT availability specific ADAM brainstem binding was used. LD correlated significantly with SERT availability (Pearson's correlations: rho = -0.57, p < 0.05). The correlations remained significant after controlling for the effects of age or gender (partial correlations: rho = -0.60, p < 0.05) but were pronounced in the female group (rho = -0.83, p < 0.01). Associations between LD and SERT availability contribute to the understanding of the central serotonergic system and further validate the use of neurophysiological approaches as indirect measures of neurochemical brain activity.
Asunto(s)
Tronco Encefálico/metabolismo , Cinanserina/análogos & derivados , Potenciales Evocados Auditivos del Tronco Encefálico/fisiología , Radiofármacos , Estimulación Acústica , Adulto , Tronco Encefálico/diagnóstico por imagen , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Masculino , Serotonina/metabolismo , Serotonina/fisiología , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
OBJECTIVE: Serotonergic dysfunction is considered to be involved in the pathophysiology of borderline personality disorder (BPD). The aim of this study was to investigate serotonin transporter availability in patients with BPD as a marker of the central serotonergic system. METHODS: Eight unmedicated patients with BPD and 9 healthy control subjects received single photon emission computed tomography (SPECT) 4 hours after injection of 185 MBq [I-123] ADAM (2-([2-([dimethylamino]methyl)phenyl]thio)). As a measure of brain serotonin transporter (SERT) availability, ratios of specific-to-nonspecific [I-123] ADAM binding for the brainstem and hypothalamus were calculated with an occipital reference. Levels of impulsiveness and depressive symptoms were assessed with the Barratt Impulsiveness Scale and the Beck Depression Inventory. RESULTS: Mean specific-to-nonspecific ratios showed a 43% higher brainstem and a 12% higher hypothalamus ADAM binding in patients, compared with control subjects. We found significant correlations of ADAM binding with both age and impulsiveness but not depression. Associations of BIS scores with ADAM binding remained significant after controlling for age and depression (r = 0.69, p < 0.01). CONCLUSION: The study provides evidence of a serotonergic dysfunction in patients with BPD and suggests a serotonergic component in the pathophysiology of the disorder. SERT binding reflected the level of impulsiveness as a common feature in BPD.
Asunto(s)
Trastorno de Personalidad Limítrofe/diagnóstico por imagen , Cinanserina/análogos & derivados , Radiofármacos , Adolescente , Adulto , Tronco Encefálico/diagnóstico por imagen , Femenino , Humanos , Hipotálamo/diagnóstico por imagen , Imagen por Resonancia Magnética , Masculino , Escalas de Valoración Psiquiátrica , Serotonina/fisiología , Proteínas de Transporte de Serotonina en la Membrana Plasmática/fisiología , Encuestas y Cuestionarios , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
[123I]ADAM (2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine) is a promising radioligand for in-vivo quantification of serotonin transporters (SERT) using single photon emission computed tomography (SPECT) in man. We performed tracer kinetic analysis in various brain regions to determine the optimum equilibrium time for SERT quantification with [123I]ADAM and SPECT. Radiosyntheses of [123I]ADAM were performed at MAP Medical Technologies Oy, Tikkakoski, Finland. Thirty healthy male volunteers (21-41 yr) received between 104 and 163 MBq [123I]ADAM intravenously as a bolus. Consecutively, multiple SPECT scans were performed between 14 and 420 min post-injection (p.i.) using a Siemens Multispect 3 camera. Reconstruction was performed applying filtered back projection with a Butterworth filter (cut-off 0.7, order 7) in 128x128 matrices. Regions of interest (ROI) were drawn manually on the individual T1-weighted magnetic resonance image (MRI) comprising midbrain/hypothalamus for specific binding to SERT, and the cerebellum as reference region. After re-orientation to the MRI, the ROI template was applied to SPECT studies. We generated time-activity curves for the ROI and calculated the ratio countstarget/countscerebellum minus 1 (=V3'') as a measure for specific SERT binding. Counts were corrected for applied activity, acquisition time and body-weight. Peak uptakes were observed between 14 and 50 min after bolus injection. Counts per voxel were highest in the midbrain/hypothalamus, 798 (max. 872, min. 728), whereas 462 counts per voxel (max. 599, min. 412) were measured in the cerebellum at a mean time of 31 min p.i. Stable values for V3'' reached 205-320 min p.i. Mean peak V3'' value was 1.43 (95% CI 171-230) for the midbrain/hypothalamus at 205 min p.i. [123I]ADAM is a useful ligand for in-vivo quantification of human SERT by means of SPECT, with a comparatively better signal-to-noise ratio compared to beta-CIT. Our data suggest that the acquisition time for the SPECT scan is optimally, under pseudo-equilibrium conditions, between 205-320 min post-bolus injection of the tracer.
Asunto(s)
Cinanserina/análogos & derivados , Radiofármacos/farmacocinética , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Adulto , Encéfalo/anatomía & histología , Encéfalo/diagnóstico por imagen , Cinanserina/farmacocinética , Humanos , Hipotálamo/anatomía & histología , Hipotálamo/diagnóstico por imagen , Imagen por Resonancia Magnética , Masculino , Mesencéfalo/anatomía & histología , Mesencéfalo/diagnóstico por imagen , Unión Proteica , Reproducibilidad de los Resultados , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
RATIONALE: To assess the paroxetine-induced serotonin transporter (SERT) occupancy (SERTocc) using in vivo (123)I-ADAM SPECT. OBJECTIVES: (123)I-ADAM SPECT was used to investigate the SERTocc induced by paroxetine in major depression disorder (MDD) patients, to compare the SERT availability in drug-free MDD patients and healthy volunteers, and to study the relationship between paroxetine plasma concentrations (Cp) and SERTocc. MATERIALS AND METHODS: Measures of SERT availability by means of (123)I-ADAM SPECT were obtained in ten MDD patients before and after 4- to 6-week treatment with paroxetine 20 mg/day. (123)I-ADAM SPECT measures of SERT availability from a group of ten previously studied age-matched healthy volunteers were used for comparison. The relationship between percentages of SERTocc and paroxetine Cp was studied using an E (max) model. RESULTS: Mean SERTocc values were 66.4 +/- 9.5% in midbrain, 63.0 +/- 9.6% in thalamus, and 61.3 +/- 10.9% in striatum. No significant differences in SERTocc were found among these three regions. No significant differences in mean SERT availability were found in any region between drug-free MDD patients (midbrain = 1.14 +/- 0.15; thalamus = 0.85 +/- 0.13; striatum = 0.70 +/- 0.07) and healthy volunteers (midbrain = 1.19 +/- 0.22; thalamus = 0.96 +/- 0.14; striatum = 0.67 +/- 0.15). The E (max) model returned a SERTocc(max) = 70.5% and a Cp(50) = 2.7 ng/ml. CONCLUSIONS: Using (123)I-ADAM SPECT, treatment with paroxetine 20 mg/day leads to more than 60% SERTocc on average in cerebral regions with known high SERT density. Data from this study do not support the existence of SERT availability differences between drug-free MDD patients and healthy volunteers. Finally, the E (max) model is suitable for the study of paroxetine Cp relationship to (123)I-ADAM SPECT-measured SERTocc. This approach may be useful for pharmacokinetic-pharmacodynamic relationships in drug development.
Asunto(s)
Encéfalo/metabolismo , Trastorno Depresivo/metabolismo , Paroxetina/farmacología , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Adulto , Encéfalo/efectos de los fármacos , Cinanserina/análogos & derivados , Cinanserina/metabolismo , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Trastorno Depresivo/tratamiento farmacológico , Trastorno Depresivo/patología , Femenino , Humanos , Radioisótopos de Yodo , Masculino , Mesencéfalo/efectos de los fármacos , Mesencéfalo/metabolismo , Persona de Mediana Edad , Paroxetina/sangre , Paroxetina/uso terapéutico , Ensayo de Unión Radioligante/métodos , Antagonistas de la Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/sangre , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Tálamo/efectos de los fármacos , Tálamo/metabolismo , Tomografía Computarizada de Emisión de Fotón Único , Resultado del TratamientoRESUMEN
Iodine-123 labeled 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine ([(123)I] ADAM) has been suggested as a promising serotonin transporter (SERT) imaging agent. Much research has been accomplished, mainly focusing on the SERT binding sites in the central nervous system (CNS). However, the biodistribution of [(123)I] ADAM using whole body autoradiography (WBAR) has never been previously described, to the best of our knowledge. In this study, we assayed the biodistribution of [(123)I] ADAM in tissues/organs removed from mice, and measured their radioactivity with a scintillation counter (SC). The results showed that the liver has the highest uptake. On the other hand, the WBAR clearly demonstrated that [(123)I] ADAM was bound to SERT-rich sites including those in the brain stem, lung, adrenal glands and intestinal mucosa. This radiotracer also accumulated in the liver, kidney, and thyroid. The results from both methods were compared; each has its own complementary role in the biodistribution studies. The SC method revealed the total amount of radiotracer accumulation in each organ, and the WBAR demonstrated more anatomical details of the radiotracer's distribution. The whole body distribution results of the radioligand using both methods explore the usage of this novel radioligand for most possible SERT binding sites, not only in the CNS but also in the peripheral nervous system and neuroendocrine tissues. These findings suggest that [(123)I] ADAM is a potentially useful imaging agent for SERT.
Asunto(s)
Autorradiografía/métodos , Proteínas Portadoras/metabolismo , Cinanserina/análogos & derivados , Cinanserina/farmacocinética , Radioisótopos de Yodo/farmacocinética , Glicoproteínas de Membrana/metabolismo , Proteínas de Transporte de Membrana , Proteínas del Tejido Nervioso , Recuento Corporal Total/métodos , Animales , Biomarcadores , Masculino , Ratones , Ratones Endogámicos ICR , Radiofármacos/farmacocinética , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Proteínas de Transporte de Serotonina en la Membrana Plasmática , Estadística como Asunto , Distribución TisularRESUMEN
In reserpinized mice the occurrence of goldthioglucose hypothalamic lesions was significantly lower than in control mice. Some protection was also conferred by serotonin-receptor blockers and by treatment with nialamide + DL-alpha-methyldopa, but the protective effect of reserpine was not reversed by serotonergic and dopaminergic agonists, alone or in combination, nor by insulin.